Clinical Trial

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 5, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-10.
Status change: Not Yet Recruiting → Recruiting 2024-06-04
Trial Details
NCT Number NCT05780905
Lead Sponsor University of Washington
Collaborators: Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Enrollment 50 participants
Start Date 2024-01-11
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-05